Literature DB >> 11374695

Radioimmunoassay to detect antitransglutaminase autoantibodies is the most sensitive and specific screening method for celiac disease.

M Bonamico1, C Tiberti, A Picarelli, P Mariani, D Rossi, E Cipolletta, M Greco, M D Tola, L Sabbatella, B Carabba, F M Magliocca, P Strisciuglio, U Di Mario.   

Abstract

OBJECTIVE: The aim of this study was to establish the most sensitive and specific screening method for celiac disease. We tested three methods based on different principles, which all detect autoantibodies against the same antigen (tissue transglutaminase).
METHODS: Sixty-two celiac children at the first biopsy (group 1), 78 celiac children on a gluten-free diet (group 2), 14 celiac children on a gluten-challenge (group 3), and 56 controls with a normal duodenal mucosa (group 4) were studied. The methods used were: 1) radioimmunoprecipitation assay using recombinant tissue transglutaminase (RIA); 2) commercial enzyme immunoassay using guinea pig tissue transglutaminase (ELISA); and 3) indirect immunofluorescence method for detection of antiendomysium antibodies (IF-EMA).
RESULTS: RIA antitransglutaminase autoantibodies were detected in 100% of group 1, 43.6% of group 2, 100% of group 3, and none of the control subjects. ELISA antitransglutaminase autoantibodies were detected in 90.3% of group 1, 9% of group 2, 78.6% of group 3, and in none of the control subjects. IF-EMA were detected in 95.2% of group 1, 11.5% of group 2, 92.3% of group 3, and 1.8% of the controls.
CONCLUSIONS: Our results demonstrate a very high sensitivity and specificity of the RIA method to detect antitransglutaminase autoantibodies in comparison to ELISA and IF-EMA assays. We can explain this finding with the use of human recombinant antigen and the increased capacity of the RIA method to detect low titers of autoantibodies. If our data are confirmed by studies on larger series, tissue transglutaminase RIA could be proposed as the best screening method for celiac patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11374695     DOI: 10.1111/j.1572-0241.2001.03754.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  7 in total

Review 1.  Accepting clocks that tell time poorly: fluid-phase versus standard ELISA autoantibody assays.

Authors:  Edwin Liu; George S Eisenbarth
Journal:  Clin Immunol       Date:  2007-09-27       Impact factor: 3.969

2.  A comparison of 13 guinea pig and human anti-tissue transglutaminase antibody ELISA kits.

Authors:  R C W Wong; R J Wilson; R H Steele; G Radford-Smith; S Adelstein
Journal:  J Clin Pathol       Date:  2002-07       Impact factor: 3.411

3.  A report on the International Transglutaminase Autoantibody Workshop for Celiac Disease.

Authors:  Marcella Li; Liping Yu; Claudio Tiberti; Margherita Bonamico; Iman Taki; Dongmei Miao; Joseph A Murray; Marian J Rewers; Edward J Hoffenberg; Daniel Agardh; Patricia Mueller; Martin Stern; Ezio Bonifacio; Edwin Liu
Journal:  Am J Gastroenterol       Date:  2009-01       Impact factor: 10.864

Review 4.  Transglutaminse 2 and EGGL, the protein cross-link formed by transglutaminse 2, as therapeutic targets for disabilities of old age.

Authors:  William Bains
Journal:  Rejuvenation Res       Date:  2013-12       Impact factor: 4.663

5.  Celiac disease in children with short stature.

Authors:  Seyed Mohsen Dehghani; Ali Akbar Asadi-Pooya
Journal:  Indian J Pediatr       Date:  2008-02       Impact factor: 1.967

6.  Diagnosis of celiac disease.

Authors:  Shinjini Bhatnagar; Nitya Tandon
Journal:  Indian J Pediatr       Date:  2006-08       Impact factor: 5.319

Review 7.  Unique Properties of Surface-Functionalized Nanoparticles for Bio-Application: Functionalization Mechanisms and Importance in Application.

Authors:  Faheem Ahmad; Mounir M Salem-Bekhit; Faryad Khan; Sultan Alshehri; Amir Khan; Mohammed M Ghoneim; Hui-Fen Wu; Ehab I Taha; Ibrahim Elbagory
Journal:  Nanomaterials (Basel)       Date:  2022-04-13       Impact factor: 5.719

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.